ÂÜÀòÂÒÂ×

Dr Frank Mathias joined Oxford Biomedica and the Board in March 2023. Dr Mathias was previously the CEO of Rentschler Biopharma SE, which he successfully developed into a leading global, full-service CDMO. Prior to this, Dr Mathias was CEO of Medigene AG, a publicly listed immuno-oncology company focusing on the development of T-cell-based cancer therapies. Over the course of his 30-year career, Dr Mathias has also served in senior roles at leading global pharmaceutical companies including Amgen, Servier and Hoechst AG, and in 2019 was awarded the title of "EY Entrepreneur of the Year" in Germany. Dr Mathias is a pharmacist by training and completed his Doctorate in Pharmacy at Paris VI University.